Metabolic, endocrinologic and cardiac effects of amisulpride: A 24-week follow-up study

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 6, 2011, Pages 189-196

  Kotan, Zeynep ^a   Ertepe, Berrin ^a   Akkaya, Cengiz ^a   Sarandol, Emre ^a   Ozkaya, Güven ^a   Kirli, Selçuk ^a  

^a NONE

Author keywords

amisulpride; efficacy; hormones; hyperprolactinemia; metabolic control; QT interval; side effects

Indexed keywords

ADIPONECTIN; AMISULPRIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN;

ADULT; AMENORRHEA; ANORGASMIA; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HUMAN; LIBIDO; MALE; MENSTRUAL IRREGULARITY; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION;

EID: 84998146012     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311426896     Document Type: Article

References (56)

1. Agelink M.W. Majewski T. Wurthmann C. Lukas K. Ullrich H. Linka T. et al. (2001) Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 21: 8–13.
2. Agid O. Kapur S. Arenovich T. Zipursky R.B. (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60: 1228–1235.
3. Akkaya C. Kaya B. Kotan Z. Sarandol A. Ersoy C. Kirli S. (2009) Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. J Psychopharmacol 23: 723–726.
4. Allison D.B. Mentore J.L. Heo M. Chandler L.P. Cappelleri J.C. Infante M.C. et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686–1696
5. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
6. Biller B.M. Luciano A. Crosignani P.G. Molitch M. Olive D. Rebar R. et al. (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 44: 1075–1084.
7. Bressan R.A. Erlandsson K. Jones H.M. Mulligan R. Flanagan R.J. Ell P.J. et al. (2003) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160: 1413–1420.
8. Brown R.P. Kocsis J.H. (1984) Sudden death and antipsychotic drugs. Hosp Community Psychiatry 35: 486–491.
9. Burns T. Bale R. (2001) Clinical advantages of amisulpride in the treatment of acute schizophrenia. J Int Med Res 29: 451–466.
10. Bushe C. Shaw M. (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 21: 768–773.
11. Bushe C. Shaw M. Peveler R.C. (2008) A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 22: 46–55.
12. Carrière P. Bonhomme D. Lempérière T. (2000) Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329.
13. De Hert M. van Eyck D. De Nayer A. (2006) Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 21: 11–15.
14. Diver M.J. Ewins D.L. Worth R.C. Bowles S. Ahlquist J.A. Fahie-Wilson M.N. (2001) An unusual form of big, big (macro) prolactin in a pregnant patient. Clin Chem 47: 346–348.
15. Dunne F. (1994) Neuroleptics and the heart. Br J Cardiol 1: 364–369.
16. Eberhard J. Lindström E. Holstad M. Levander S. (2007) Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 115: 268–276.
17. Fleischhacker W.W. Cetkovich-Bakmas M. De Hert M. Hennekens C.H. Lambert M. et al. (2008) Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 69: 514–519.
18. Gründer G. Wetzel H. Schlösser R. Anghelescu I. Hillert A. Lange K. et al. (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45: 89–97.
19. Hattori N. (1996) The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. J Clin Endocrinol Metab 81: 586–590.
20. Hummer M. Huber J. (2004) Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 20: 189–197.
21. Isbister G.K. Balit C.R. Macleod D. Duffull S.B. (2010) Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol 30: 391–395.
22. Jung D.U. Conley R.R. Kelly D.L. Kim D.W. Yoon S.H. Jang J.H. et al. (2006) Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 67: 1391–1396.
23. Kabinoff G.S. Toalson P.A. Healey K.M. McGuire H.C. Hay D.P. (2003) Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim Care Companion J Clin Psychiatry 5: 6–14.
24. Kopecek M. Bears M. Svarc J. Dockery C. Horacek J. (2004) Hyperprolactinemia after low dose of amisulpride Neuro Endocrinol Lett 25: 419–422.
25. Kuruvilla A. Peedicayil J. Srikrishna G. Kuruvilla K. Kanagasabapathy A.S. (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19: 603–606.
26. Leucht S. Busch R. Hamann J. Kissling W. Kane J.M. (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57: 1543–1549.
27. Leucht S. Corves C. Arbter D. Engel R.R. Li C. Davis J.M. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41.
28. Leucht S. Pitschel-Walz G. Engel R.R. Kissling W. (2002) Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159: 180–190.
29. Leucht S. Wagenpfeil S. Hamann J. Kissling W. (2004) Amisulpride is an “atypical” antipsychotic associated with low weight gain. Psychopharmacology (Berl) 173: 112–115.
30. Lynch M.J. Woods J. George N. Gerostamoulos D. (2008) Fatality due to amisulpride toxicity: a case report. Med Sci Law 48: 173–177.
31. Melkersson K.I. Hulting A.L. Rane A.J. (2001) Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51: 317–324.
32. Möller H.J. (2000) Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatr Scand Suppl 400: 17–22.
33. Mortimer A. Martin S. Lôo H. Peuskens J. for the SOLIANOL Study Group (2004) A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 19: 63–69.
34. Mortimer A.M. (2003) Antipsychotic treatment in schizophrenia: atypical options and NICE guidance. Eur Psychiatry 18: 209–219.
35. Mortimer A.M. (2004) Novel antipsychotics in schizophrenia. Expert Opin Investig Drugs 13: 315–329.
36. Mortimer A.M. (2009) Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr Dis Treat 5: 267–277.
37. Newcomer J.W. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19: 1–93.
38. Paparrigopoulos T. Liappas J. Tzavellas E. Mourikis I. Soldatos C. (2007) Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 31: 92–96.
39. Peuskens J. De Hert M. Mortimer A. for the SOLIANOL Study Group (2007) Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 22: 145–152.
40. Peveler R.C. Branford D. Citrome L. Fitzgerald P. Harvey P.W. Holt R.I. et al. (2008) Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 22: 98–103.
41. Rein W. Coulouvrat C. Dondey-Nouvel L. (2000) Safety profile of amisulpride in short- and long-term use. Acta Psychiatr Scand Suppl 400: 23–27.
42. Rettenbacher M.A. Hummer M. Hofer A. Baumgartner S. Ebenbichler C. Edlinger M. et al. (2007) Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol 21: 400–404.
43. Russell J.M. Mackell J.A. (2001) Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15: 537–551.
44. Scatton B. Claustre Y. Cudennec A. Oblin A. Perrault G. Sanger D.J. et al. (1997) Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 2: 29–36.
45. Schoemaker H. Claustre Y. Fage D. Rouquier L. Chergui K. Curet O. et al. (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280: 83–97.
46. Sechter D. Peuskens J. Fleurot O. Rein W. Lecrubier Y. for the Amisulpride Study Group (2002) Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 27: 1071–1081.
47. Serri O. Chik C.L. Ur E. Ezzat S. (2003) Diagnosis and management of hyperprolactinemia. CMAJ 169: 575–581.
48. Simpson G.M. Angus J.W. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11–19.
49. Stanniland C. Taylor D. (2000) Tolerability of atypical antipsychotics. Drug Saf 22: 195–214.
50. Svestka J. Synek O. Tomanová J. Rodáková I. Cejpková A. (2007) Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 28: 881–888.
51. Taylor D.M. McAskill R. (2000) Atypical antipsychotics and weight gain—a systematic review. Acta Psychiatr Scand 101: 416–432.
52. Tschoner A. Engl J. Laimer M. Kaser S. Rettenbacher M. Fleischhacker W.W. et al. (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61: 1356–1370.
53. Tschoner A. Engl J. Rettenbacher M. Edlinger M. Kaser S. Tatarczyk T. et al. (2009) Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 42: 29–34.
54. Tuomisto J. Männistö P. (1985) Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 37: 249–332.
55. Ungvári G. (1982) Neuroleptic treatment and unexpected death. Fortschr Neurol Psychiatr 50: 267–273.
56. Wetzel H. Wiesner J. Hiemke C. Benkert O. (1994) Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res 28: 461–473.